Pre-Menstrual Syndrome Treatment Market By Drug (Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Premenstrual syndrome (PMS) is a medical condition in women that occurs during childbearing age. It is estimated that more than one in three women suffers from PMS, and one in every twenty women demonstrates life-disturbing symptoms. Premenstrual dysphoric disorder (PMDD) is a further severe form of PMS and demonstrates more severe symptoms of PMS, often interfering with social activities, work, and emotional balance. PMDD occurs in 3% to 5% of menstruating women. Though the exact cause of PMS is unknown, it is reported that fluctuating levels of hormones (estrogen and progesterone) are related to PMS symptoms. The treatment regimen for PMS is temporary, i.e., administered only for symptom management before the onset of the menstrual cycle. Education, nutrition, exercise, and medication together form the complete layout of the PMS treatment module.

The report titled "Premenstrual Syndrome Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2016–2024" offers strategic insights into the overall premenstrual syndrome treatment market, along with the market size and estimates for the duration of 2014–2024. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. The drug types studied for analyzing the overall global premenstrual syndrome treatment market are majorly segmented into analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics, and benzodiazepines.

Geographically, the global premenstrual syndrome treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global premenstrual syndrome treatment market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive landscape of the global premenstrual syndrome treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global premenstrual syndrome treatment market. In-depth competitive environment analysis and historical (2014) market size data are also provided in the report.

Based on the type of drug, the global premenstrual syndrome treatment market is segmented as follows:

  • Analgesics (pain killers)
  • Oral contraceptive pills (OCPs)
  • Gonadotropin-releasing hormone (GnRH)
  • Antidepressants
  • Ovarian Suppressors
  • Diuretics
  • Benzodiazepines

NSAIDs and paracetamol are common pain relievers used to treat PMS. This market is dominated by over-the-counter drugs, which are inexpensive and widely available. For depression and anxiety, particularly in patients with PMDD, drugs such as SSRIs (commonly fluoxetine and sertraline) are commonly prescribed. GnRH, i.e., synthetic hormones, are prescribed to initiate temporary menopause in patients with severe PMS. It is observed that the demand for hormone-based PMS treatments is on a perpetual rise and will continue through the forecast period.

For the purpose of this study, the global premenstrual syndrome treatment market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

At present, North America and Europe dominate the premenstrual syndrome treatment market due to an increase in the prevalence of the syndrome and higher awareness of the syndrome and prevailing treatment options. The Asia Pacific, the Middle East, and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. A large pool of females of childbearing age, a growing literacy rate, and a working population significantly contribute to growing opportunities in the region. A growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market's growth.

Frequently Asked Questions:

The market for Pre-Menstrual Syndrome Treatment Market is expected to reach US$ 4,985.7 Mn in 2024.

The Pre-Menstrual Syndrome Treatment Market is expected to see significant CAGR growth over the coming years, at 2.0%

The report is forecasted to 2016-2024.

The base year of this report is 2015.

Alva-Amco Pharmacal Cos., Inc., Bayer, Inc.,Chattem, Inc. (Sanofi),DEKK-TEC, Inc.,G. R. Lane Health Products Ltd are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Mar 2017
Category:  Pharmaceuticals
Report ID:   58371
Report Format:   PDF
Pages:   120
Rating:    4.4 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support